secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prime Medicine, Inc. (PRME)
CIK:        0001894562
Form:       8-K
Filed at:   2025-07-31T23:59:59+00:00
Accession:  0001628280-25-037076
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prime Medicine prices $125M equity offering; net proceeds ~$120.2M for R&D
--------------------------------------------------------------------------

- Offering of 38M shares at $3.30/share; underwriters have 30-day option for 5.7M additional shares.
- Estimated net proceeds of $120.2M after underwriting discounts and expenses.
- Proceeds to fund Wilson's Disease and Alpha-1 Antitrypsin Deficiency programs; remainder for working capital.
- Underwriting led by TD Securities and BMO Capital Markets; expected close August 1, 2025.
- Cystic Fibrosis Foundation to purchase 1,818,181 shares without any underwriting discounts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894562/000162828025037076/0001628280-25-037076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894562/000162828025037076/prme-20250730.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-037076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer